![]() In patients with inadequate initial response, additional response after this time is unlikely. Response to treatment should be evaluated after 2 months. Hence, some patients that respond insufficiently to 60 mg may benefit from a higher dose. The plasma concentration of duloxetine displays large inter-individual variability (see section 5.2). Dosages above 60 mg once daily, up to a maximum dose of 120 mg per day administered in evenly divided doses, have been evaluated from a safety perspective in clinical trials. The starting and recommended maintenance dose is 60 mg daily with or without food. Dose escalation should be based upon clinical response and tolerability.Īfter consolidation of the response, it is recommended to continue treatment for several months, in order to avoid relapse. In patients with insufficient response to 60 mg, escalation up to 90 mg or 120 mg may therefore be considered. In patients with co-morbid major depressive disorder, the starting and maintenance dose is 60 mg once daily (please see also dosing recommendation above).ĭoses up to 120 mg per day have been shown to be efficacious and have been evaluated from a safety perspective in clinical trials. In patients with insufficient response the dose should be increased to 60 mg, which is the usual maintenance dose in most patients. The recommended starting dose in patients with generalised anxiety disorder is 30 mg once daily with or without food. In patients responding to duloxetine, and with a history of repeated episodes of major depression, further long-term treatment at a dose of 60 to 120 mg/day could be considered. Therapeutic response is usually seen after 2-4 weeks of treatment.Īfter consolidation of the antidepressive response, it is recommended to continue treatment for several months, in order to avoid relapse. However, there is no clinical evidence suggesting that patients not responding to the initial recommended dose may benefit from dose up-titrations. Dosages above 60 mg once daily, up to a maximum dose of 120 mg per day have been evaluated from a safety perspective in clinical trials. The starting and recommended maintenance dose is 60 mg once daily with or without food. Date of first authorisation/renewal of the authorisation 6.6 Special precautions for disposal and other handling.4.7 Effects on ability to drive and use machines.4.5 Interaction with other medicinal products and other forms of interaction. ![]() 4.4 Special warnings and precautions for use.4.2 Posology and method of administration.Show table of contents Hide table of contents
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |